{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:21:16Z","timestamp":1783959676716,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In 2018, the Chinese Guidelines for Diagnosis and Treatment of HIV\/AIDS recommended the adoption of the efavirenz 400\u202fmg-based TLE (tenofovir disoproxil fumarate (TDF)\u202f+\u202flamivudine (3TC)\u202f+\u202fefavirenz (EFV)) regimen as the primary first-line treatment for ART-naive HIV-1 infected adults in China. However, the cost-effectiveness of different TLE treatment strategies remains uncertain. This study aimed to evaluate the cost-effectiveness of various TLE treatment strategies for ART-naive HIV-1 infected adults in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A decision-tree Markov state transition model was employed to assess the cost-effectiveness of various TLE treatment strategies over a 10-year timeframe, from a societal perspective. Input parameters were obtained from published literature and publicly accessible information. Local data from the latest sources were used as input parameters whenever possible. The main outcome measure was the incremental costs per quality-adjusted life years (QALYs) gained. Sensitivity analyses were performed to investigate model uncertainties and determine break-even prices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to the multiple-tablet regimen (MTR) consisting of efavirenz 400\u202fmg-based TLE (TLE400) and efavirenz 600\u202fmg-based TLE (TLE600), the single-tablet regimen (STR) of TLE400 exhibited a 10-year cost of 130733.8 CNY (compared to 122939.7 CNY and 126184.3 CNY, respectively) and an expected QALYs of 6.45 (compared to 6.27 QALYs and 6.32 QALYs, respectively) per HIV-1 patient in China. Consequently, the incremental cost-effectiveness ratios (ICERs) were 41021.6 CNY\/QALY gained (equivalent to US$ 6071.2 per QALY gained) and 34996.2 CNY\/QALY gained (equivalent to US$ 5179.4 per QALY gained) for TLE400 STR compared to TLE400 MTR and TLE600 MTR, respectively. The ICER for TLE400 MTR compared to TLE600 MTR was 54076.7 CNY\/QALY gained (equivalent to US$ 8003.4 per QALY gained). Deterministic sensitivity analysis indicated that adherence rates to ART had the most significant influence on all three strategies. In probabilistic sensitivity analysis, TLE400 STR demonstrated a 71.4% probability of being highly cost-effective nationwide, based on the one-time national-level GDP per capita.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the context of treating HIV-1 infected adults in China, the STR of TLE400 demonstrated cost-effectiveness when compared to both the MTR of TLE400 and the MTR of TLE600.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1429461","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:26:37Z","timestamp":1746681997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Haijun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref2","year":"2024"},{"key":"ref3","first-page":"1","article-title":"The AIDS epidemic situation and the achievement of prevention and control in China","volume":"11","author":"Xiwen","year":"1999","journal-title":"J Med Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.46234\/ccdcw2021.249","article-title":"Research Progress in the epidemiology of HIV\/AIDS in China","volume":"3","author":"He","year":"2021","journal-title":"China CDC Wkly"},{"key":"ref5","year":"2021"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M14-0293","article-title":"Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data","volume":"161","author":"Mollan","year":"2014","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/0975-1483.104369","article-title":"Association between medication adherence outcomes and adverse drug reactions to highly active antiretroviral therapy in Indian human immunodeficiency virus-positive patients","volume":"4","author":"Rajesh","year":"2012","journal-title":"J Young Pharm"},{"key":"ref8","year":"2015"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12879-021-05802-8","article-title":"Pharmacodynamics of efavirenz 400 mg in treatment-na\u00efve Chinese HIV-infected patients in a prospective cohort study","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijid.2022.01.051","article-title":"Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study","volume":"117","author":"Xiao","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.12607","article-title":"Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study","volume":"19","author":"Guo","year":"2018","journal-title":"HIV Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/22221751.2020.1752609","article-title":"Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial","volume":"9","author":"Chen","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3760\/cma.j.cn112138-20211006-00676","article-title":"Chinese Guidelines for HIV\/AIDS Diagnosis and Treatment","volume":"2021","year":"2021","journal-title":"Chin J Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/hiv.12912","article-title":"Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India","volume":"21","author":"Dravid","year":"2020","journal-title":"HIV Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1060028016682531","article-title":"Once-daily, single-tablet regimens for the treatment of HIV-1 infection","volume":"40","author":"Truong","year":"2015","journal-title":"P T"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/17425255.2018.1498840","article-title":"The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection","volume":"14","author":"Dubrocq","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref20","year":""},{"key":"ref21","volume-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Liu","year":"2020"},{"key":"ref22","year":"2022"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"Carey","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5576612","DOI":"10.1155\/2021\/5576612","article-title":"Effect of traditional Chinese medicine therapy on the trend in CD4(+) T-cell counts among patients with HIV\/AIDS treated with antiretroviral therapy: a retrospective cohort study","volume":"2021","author":"Wang","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-6405-8-2","article-title":"Long-term CD4+ lymphocyte response following HAART initiation in a US military prospective cohort","volume":"8","author":"Lifson","year":"2011","journal-title":"AIDS Res Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/QAD.0b013e32834e87e6","article-title":"Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection","volume":"26","author":"Mauskopf","year":"2012","journal-title":"AIDS"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40121-015-0071-0","article-title":"Cost-effectiveness of dolutegravir in HIV-1 treatment-naive and treatment-experienced patients in Canada","volume":"4","author":"Despi\u00e9gel","year":"2015","journal-title":"Infect Dis Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12962-019-0195-2","article-title":"Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients","volume":"17","author":"Punekar","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1\u2013infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1371\/journal.pone.0170661","article-title":"Single-versus multiple-tablet HIV regimens: adherence and hospitalization risks","volume":"22","author":"Sutton","year":"2016","journal-title":"Am J Manag Care"},{"key":"ref31","year":"2022"},{"key":"ref32","volume-title":"Single AIDS family different antiviral treatment strategy, cost-effectiveness and utility research","author":"Ma","year":"2016"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3969\/j.issn.1002-3429.2020.11.007","article-title":"Cost-effectiveness analysis of tenofovir dipivoxil in adults with initially treated acquired immune deficiency syndrome","volume":"33","author":"Chao","year":"2020","journal-title":"Clin Misdiagn Misther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/hiv.12562","article-title":"Antiretroviral pill count and clinical outcomes in treatment-na\u00efve patients with HIV infection","volume":"19","author":"Young","year":"2018","journal-title":"HIV Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1524-4733.2008.00326.x","article-title":"A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy","volume":"11","author":"Kauf","year":"2008","journal-title":"Value Health"},{"key":"ref36","volume-title":"China health statistical yearbook 2021","year":"2021"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.13419\/j.cnki.aids.2021.08.29","article-title":"Progress in antiviral treatment of HIV with efavirenz 400 mg dose","volume":"27","author":"Li Hui","year":"2021","journal-title":"Chin J AIDS STD"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/hiv.12695","article-title":"Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-na\u00efve youth in the HIV research network","volume":"20","author":"Griffith","year":"2019","journal-title":"HIV Med"},{"key":"ref39","year":"2003"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vhri.2018.08.001","article-title":"Cost-effectiveness of Dolutegravir as a first-line treatment option in the HIV-1-infected treatment-naive patients in Russia","volume":"16","author":"Tremblay","year":"2018","journal-title":"Value Health Reg Iss"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.mjafi.2013.08.005","article-title":"Rate of decline in CD4 count in HIV patients not on antiretroviral therapy","volume":"70","author":"Patrikar","year":"2014","journal-title":"Med J Armed Forces India"},{"key":"ref42","year":"2022"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1429461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:26:42Z","timestamp":1746682002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1429461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":42,"alternative-id":["10.3389\/fpubh.2025.1429461"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1429461","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1429461"}}